Enanta Pharmaceuticals Inc (ENTA)

[willyw]

As you know I bought a small amount of Pardes (at this moment green)- not so much as a hedge, but as a sort of surrogate real time notification system, and to force myself to pay more attention to the competition.
One could do the same with other covid compounds being developed.

When I look at Enanta's slide 20 (2022) I see another competitor with a PI. They are in phase 2/3 and project once a day dosing.
It is even more thinly traded than ENTA and in spite of possibly being a contender their stock has been flat- perhaps the opposite of AVIR in a few ways. SGIOY (?). It seems wholly off the radar. All things being the same- approval before Pardes.
If PFE will have the major covid antiviral- whose will unseat PFE's?
Any thoughts?

One unknown in this, which I expect that no one knows the answers, are two factors (perhaps this would be better as a separate post)
1) The trajectory of covid which could mutate into another delta like scenario which escapes vaccines OR conversely promptly winds down to endemic
2) The path of EUA (Emergency Use Authorization) and it's effects upon drugs in development. The outcomes for drugs being developed could change radically (along with their stock price) contingent upon -for example purposes only- if the EUA extended into next year versus if it ended next month.
I'm forced to imagine how the EUA will impact drugs in development- both in best and worst case scenarios.